William K. Oh, MD | Authors

Articles

Evaluating Significance of ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer

November 12, 2019

William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.

Dr. Oh Discusses the Use of Abiraterone and Docetaxel in Prostate Cancer

January 17, 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with metastatic castration-resistant prostate cancer.

The Utility of Cabazitaxel

December 02, 2014

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.

Validating Gene Signatures in mCRPC

May 06, 2014

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).

A Biomarker Development Trial of Satraplatin in Patients With mCRPC

February 01, 2014

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.